دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Ongoing Concerns Regarding Finasteride for the Treatment of Male-Pattern Androgenetic Alopecia
Roger S. Ho, MD, MS, MPH
doi : 10.1001/jamadermatol.2020.3384
JAMA Dermatol. 2021;157(1):25-26
Since its approval for the treatment of male-pattern androgenetic alopecia by the United States Food and Drug Administration in 1997, finasteride has continued to be at the center of many controversies regarding its adverse events. Although sexual adverse events were included in the original label of finasteride, little attention was initially paid to the 2002 elimination of the word “all” in the drug monograph1 regarding sexual adverse events, changing the language from “resolution occurred in all men who discontinued therapy” to “resolution occurred in men who discontinued therapy.” However, mounting evidence, such as case reports and small surveys, prompted the addition of the adverse reaction “sexual dysfunction that continued after discontinuation of treatment, including erectile dysfunction, libido disorders, ejaculation disorders, and orgasm disorders” in 2012 under the postmarketing experience section of the drug monograph.1 Although a definitive causal relationship had yet to be established, the labeling change captured immediate media attention. Shortly thereafter, many pharmacovigilance databases saw an uptick in adverse event reports for finasteride, including controversial adverse events such as suicidality and mental health concerns.2 These subsequent reports of suicidality and psychological adverse events, together with the well-publicized sexual adverse events, resulted in the coining of the term “post-finasteride syndrome” and the establishment of the Post-Finasteride Syndrome Foundation in 2012.3
Economics of Teledermatology—Does the Math Add Up?
April W. Armstrong, MD, MPH; Indira Singh, MD
doi : 10.1001/jamadermatol.2020.4067
JAMA Dermatol. 2021;157(1):27-28
Teledermatology has the potential to improve timely access to care.1 This technology-enabled delivery of dermatology care has evolved over the past 2 decades, with increasing evidence demonstrating its accuracy and reliability.2 For the management of certain inflammatory skin conditions, clinical outcomes are equivalent between patients who were treated online and those treated in person.3
Investigation of Suicidality and Psychological Adverse Events in Patients Treated With Finasteride
David-Dan Nguyen, MPH; Maya Marchese, MSc; Eugene B. Cone, MD
doi : 10.1001/jamadermatol.2020.3385
JAMA Dermatol. 2021;157(1):35-42
This case-control study investigates the association of suicidality (ideation, attempt, and completed suicide) and psychological adverse events (depression and anxiety) with use of finasteride in a global database.
Association of Secukinumab Treatment With Tuberculosis Reactivation in Patients With Psoriasis, Psoriatic Arthritis, or Ankylosing Spondylitis
Boni E. Elewski, MD; John W. Baddley, MD, MSPH; Atul A. Deodhar, MD
doi : 10.1001/jamadermatol.2020.3257
JAMA Dermatol. 2021;157(1):43-51
This pooled cohort study evaluates the safety of newer biological agents for the treatment of tuberculosis infection and activation in patients with psoriasis, psoriatic arthritis, and ankylosing spondylitis.
Cost Minimization Analysis of a Teledermatology Triage System in a Managed Care Setting
Adam Zakaria, BA; Theodore A. Miclau, MS; Toby Maurer, MD
doi : 10.1001/jamadermatol.2020.4066
JAMA Dermatol. 2021;157(1):52-58
This cost minimization analysis compares the organization-wide cost of managing newly referred dermatology patients within a teledermatology triage system vs a conventional dermatology care model.
Assessment of Age, Period, and Birth Cohort Effects and Trends in Merkel Cell Carcinoma Incidence in the United States
Daniel Jacobs, BA; Huang Huang, MPH; Kelly Olino, MD
doi : 10.1001/jamadermatol.2020.4102
JAMA Dermatol. 2021;157(1):59-65
This cross-sectional study uses data from the Surveillance, Epidemiology, and End Results Program to evaluate the associations of patient age, calendar period of diagnosis, and birth cohort with the increasing incidence of Merkel cell carcinoma and provide new incidence projections to 2030.
Randomized Trial Replication Using Observational Data for Comparative Effectiveness of Secukinumab and Ustekinumab in PsoriasisA Study From the British Association of Dermatologists Biologics and Immunomodulators Register
Zenas Z. N. Yiu, PhD; Kayleigh J. Mason, PhD; Philip J. Hampton, PhD
doi : 10.1001/jamadermatol.2020.4202
JAMA Dermatol. 2021;157(1):66-73
This comparative effectiveness research study examines observational data from the British Association of Dermatologists Biologics and Immunomodulators Register and compares them with clinical trial data to determine the effectiveness of 2 psoriasis medications.
Tofacitinib for the Treatment of Nail Lesions and Palmoplantar Pustulosis in Synovitis, Acne, Pustulosis, Hyperostosis, and Osteitis Syndrome
Chen Li, MD; Zhaohui Li, MD; Yihan Cao, MD
doi : 10.1001/jamadermatol.2020.3095
JAMA Dermatol. 2021;157(1):74-78
This case series study examines the use of tofacitinib for treating nail involvement in Chinese women with synovitis, acne, pustulosis, hyperostosis, and osteitis syndrome.
Incidence of New Primary Cutaneous Melanoma in Patients With Metastatic Melanoma Treated With Immune Checkpoint InhibitorsA Single-Center Cohort Study
Japbani K. Nanda, BS; Stephen W. Dusza, DrPH; Cristian Navarrete-Dechent, MD
doi : 10.1001/jamadermatol.2020.3671
JAMA Dermatol. 2021;157(1):79-83
This observational cohort study assesses the incidence of new cutaneous melanoma in patients treated with ipilimumab, nivolumab, and/or pembrolizumab for metastatic melanoma.
Association of Mohs Micrographic Surgery vs Wide Local Excision With Overall Survival Outcomes for Patients With Melanoma of the Trunk and Extremities
Addison M. Demer, MD; Jamie L. Hanson, MD; Ian A. Maher, MD
doi : 10.1001/jamadermatol.2020.3950
JAMA Dermatol. 2021;157(1):84-89
This retrospective cohort study analyzes data from the National Cancer Database regarding outcomes of Mohs micrographic surgery versus wide local excision in treatment of melanomas that occur in the trunk and extremities.
Low-Dose Total Skin Electron Beam Therapy as Part of a Multimodality Regimen for Treatment of Sézary SyndromeClinical, Immunologic, and Molecular Analysis
Joseph S. Durgin, BA; Neha N. Jariwala, MD; Maria Wysocka, PhD
doi : 10.1001/jamadermatol.2020.3958
JAMA Dermatol. 2021;157(1):90-95
This case series discusses 3 patients with Sézary syndrome who were treated with low-dose total skin electron beam therapy as part of a multimodality systemic regimen.
Consensus Statement for the Management and Treatment of Port-Wine Birthmarks in Sturge-Weber Syndrome
Sara Sabeti, BS; Karen L. Ball, BS; Craig Burkhart, MS, MPH, MD
doi : 10.1001/jamadermatol.2020.4226
JAMA Dermatol. 2021;157(1):98-104
This consensus statement presents recommendations for treatment of port-wine birthmarks.
Trichodysplasia Spinulosa in a Kidney Transplant Recipient
Anna Sonstegard, MD; Marc Grossman, MD; Amit Garg, MD
doi : 10.1001/jamadermatol.2020.3986
JAMA Dermatol. 2021;157(1):105
This case report describes a kidney transplant recipient with pink follicular papules with central white spicules on her face, ears, and extremities.
Erythema Ab Igne
Nicole Kn?pfel, MD; Lisa Weibel, MD
doi : 10.1001/jamadermatol.2020.3995
JAMA Dermatol. 2021;157(1):106
This case report describes a teenage girl with a medical history of an eating disorder who presented with livedolike skin changes on the abdomen and was subsequently diagnosed with erythema ab igne.
Rapidly Progressive Stiffness and Nodularity of Both Hands in a Middle-aged Woman
Pin-Hsuan Chiang, MD; Ren-Feng Liu, MD
doi : 10.1001/jamadermatol.2020.4386
JAMA Dermatol. 2021;157(1):107-108
A middle-aged woman presented with rapidly progressive redness and stiffness of both hands, accompanied by 2 months of multiple finger joint and right shoulder pain. What is your diagnosis?
Reddish-Brown Hematomalike Annular Plaque in a Healthy Patient’s Axilla
Vicente Exp?sito-Serrano, MD; Jorge Roman? de Gabriel, PhD; Empar Saez Artacho, PhD
doi : 10.1001/jamadermatol.2020.4563
JAMA Dermatol. 2021;157(1):109-110
A healthy man in his 50s presents with an asymptomatic, reddish hematomalike plaque with a brownish peripheral border in his left axilla, and a biopsy is positive for CD31, CD34, and D2-40 and negative for Wilms tumor 1. What is your diagnosis?
Diagnosis, Clinical Features, and Management of Patients With Granulomatous Cheilitis
Joseph S. Durgin, BA; Olaf Rodriguez, MD; Thomas Sollecito, DMD
doi : 10.1001/jamadermatol.2020.4383
JAMA Dermatol. 2021;157(1):112-114
This case series study of patients with granulomatous cheilitis at a tertiary referral center seeks to better describe the demographic characteristics, presenting features, associated disorders, and response to treatment of granulomatous cheilitis.
Accuracy and Cost-effectiveness of a Telemedicine Triage Initiative for Patients With Suspected Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis
Christine Y. Wong, MD; Roy M. Colven, MD; Nicole S. Gibran, MD
doi : 10.1001/jamadermatol.2020.4490
JAMA Dermatol. 2021;157(1):114-115
This retrospective analysis assesses triage accuracy and transportation costs associated with implementation of a multidisciplinary store-and-forward telemedicine triage system for patients with suspected Stevens-Johnson syndrome and toxic epidermal necrolysis.
Pain Severity and Management of Hidradenitis Suppurativa at US Emergency Department Visits
Matthew T. Taylor, BA; Lauren A. V. Orenstein, MD; John S. Barbieri, MD, MBA
doi : 10.1001/jamadermatol.2020.4494
JAMA Dermatol. 2021;157(1):115-117
This repeated cross-sectional study compares pain severity and rates of prescriptions for opioids in emergency department visits for hidradenitis suppurative with those in visits for atopic dermatitis or psoriasis.
Spectrum of Nail Sequelae in Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis
ShengYang Bertrand Lian, MBBS; Choon Chiat Oh, MBBS, MRCP; Yi Wei Yeo, MBBS, MRCP, MMed (Internal Medicine)
doi : 10.1001/jamadermatol.2020.4664
JAMA Dermatol. 2021;157(1):117-119
This case series documents the incidence of various nail changes as sequalae to Stevens-Johnson syndrome/toxic epidermal necrolysis.
Fibroblast Growth Factor Receptor Inhibitors and Nonuremic Calciphylaxis
Jesse Hirner, MD; James M. Cleary, MD, PhD; Anthony Sheets, MD, PhD
doi : 10.1001/jamadermatol.2020.4076
JAMA Dermatol. 2021;157(1):119-121
This case report describes a woman in her 70s with type 2 diabetes, hypertension, idiopathic thrombocytopenia, and metastatic cholangiocarcinoma with an fibroblast growth factor receptor 2 translocation.
Use of Topical Sirolimus (Rapamycin) for Treating Confluent and Reticulated Papillomatosis
David J. Kurtyka, MS; Katherine T. Burke, MD; Cynthia Marie Carver DeKlotz, MD
doi : 10.1001/jamadermatol.2020.4083
JAMA Dermatol. 2021;157(1):121-123
This case report describes an adolescent male with a history of prediabetes and obesity who presented with a diagnosis of confluent and reticulated papillomatosis with features of acanthosis nigricans.
Association Between Early Severe Cardiovascular Events and Ustekinumab Treatment?
Joel M. Gelfand, MD, MSCE; Erica D. Dommasch, MD, MPH; Nehal N. Mehta, MD, MSCE
doi : 10.1001/jamadermatol.2020.4456
JAMA Dermatol. 2021;157(1):123
To the Editor Poizeau et al1 conducted a case-crossover study of ustekinumab and advised caution when prescribing this biologic in patients with psoriasis at high cardiovascular (CV) risk. Their conclusion is based on their finding that patients with 2 or more CV risk factors (an unconventional definition of high risk) or history of CV events had increased odds of receiving ustekinumab in the 0 to 6 months before experiencing a severe CV event compared with the 12- to 6-month period before the event (odds ratio, 4.17; 95% CI, 1.19-14.59).1
Association Between Early Severe Cardiovascular Events and Ustekinumab Treatment?—Reply
Florence Poizeau, MD; Emmanuel Nowak, PhD; Alain Dupuy, MD, PhD
doi : 10.1001/jamadermatol.2020.4457
JAMA Dermatol. 2021;157(1):123-124
In Reply We thank Gelfand et al for their interest in our study.1 Their main criticism relates to the appropriateness of the case-crossover design, while our study used a case-time-control design. However, the case-crossover design is an adequate theoretical framework to discuss their objections to our study. Gelfand et al refer to 2 concepts related to time that merit clear distinction.
Transposed Author Names
doi : 10.1001/jamadermatol.2020.4709
JAMA Dermatol. 2021;157(1):124
in the Clinicopathological Challenge article “A Translucent Nodule of the Nipple in an Elderly Male Patient,”1 published online first on January 8, 2020, and in the March 2020 print issue of JAMA Dermatology, the authors’ first and last names were transposed. The correct author names are Dario Ahangari, MD; Pascal Van Eeckhout, MD; and Isabelle Tromme, MD, PhD. The article has been corrected online.
Errors in the Abstract, Introduction, Methods, and Discussion Sections
doi : 10.1001/jamadermatol.2020.5204
JAMA Dermatol. 2021;157(1):124
in the Original Investigation titled “Association of Secukinumab Treatment With Tuberculosis Reactivation in Patients With Psoriasis, Psoriatic Arthritis, or Ankylosing Spondylitis,” which published online September 30, 2020,1 there were errors in the Abstract, Introduction, Methods, and Discussion sections. The study type was incorrectly identified as a qualitative study. It is a pooled cohort study. The SRQR reporting guideline was not followed. The authors used SAS, version 9.4 (SAS Institute, Inc) for all analyses, and all clinical trial data are stored and pooled in the Global Programming System. This article was corrected online.
JAMA Dermatology
doi : 10.1001/jamadermatol.2020.3854
JAMA Dermatol. 2021;157(1):19
Mission Statement: JAMA Dermatology publishes information concerning the skin, its diseases, and their treatment. Its mission is to explicate the structure and function of the skin and its diseases and the art of using this information to deliver optimal medical and surgical care to the patient. We attempt to enhance the understanding of cutaneous pathophysiology and improve the clinician’s ability to diagnose and treat skin disorders. This journal has a particular interest in publishing clinical and laboratory studies that reveal new information pertinent to the interests and needs of the medical dermatologist, dermatologic surgeon, and all those concerned with state-of-the-art care of cutaneous disease. We believe that knowledge derived from well-designed clinical trials and studies of cost-effectiveness are especially important for improving the practice of dermatology. Studies that increase the understanding of the outcome of treatment or the means by which the burden of dermatologic disease can be measured and reduced to promote the health of patients with skin disease will receive special priority. The journal regularly publishes reports on clinical investigations, editorials, and reviews. It also features reports and discussions on clinicopathologic correlations; clinical disorders of unique didactic value; pharmacologic, medical and surgical therapeutics; and ethical, moral, socioeconomic, and political issues.
